Davis Gregory D reported tax withholding involving 1,630 shares of SANGAMO THERAPEUTICS, INC at $0.17 for −$284 on May 25, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
Head of Research & Technology
Head of Research & Technology
Filed May 27, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$284.11Shares × reported price
Shares traded
1,630Common Stock
Price per share
$0.17Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
113,654Direct
Trade date
May 25, 2026Tax withholding
Filed
May 27, 2026, 7:30 PM ET2-day reporting delay
Accession
0002041855-26-000010Code F · Transaction 91423
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SGMO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SGMO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +12%1w ago 0%1d ago 0%
Returns since7d 0%30d 0%90d 0%180d1y

Footnotes in full

F1: Represents shares underlying the portion of an RSU grant that vested on May 25, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2026 of $0.1743/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2: Includes: 3,031 shares from the May 25, 2026 vesting installment of the Reporting Person's February 25, 2025 RSU grant and the remaining 32,633 shares will vest in 7 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.